Early highly effective therapies group (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03535298 (ClinicalTrials.gov) | January 3, 2019 | 14/5/2018 | Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Early Highly Effective Therapies Group;Drug: Escalation Therapies Group | The Cleveland Clinic | University of Nottingham | Recruiting | 18 Years | 60 Years | All | 800 | Phase 4 | United States;United Kingdom |